ReviewFrontiers in cell and developmental biology2025
TRIM21: a multifaceted regulator in cancer.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Phase Separation of TRIM21 Modulates PTPN14 Stability to Drive Flow-Dependent Endothelial Activation and Atherogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TRIM21 autoantibodies are associated with blood-brain barrier dysfunction in a subgroup of neuromyelitis optica spectrum disorder.Acta neuropathologica communications · 2026Article
- TRIM21-Mediated ubiquitination of FBL suppresses PI3K/AKT signaling and tumor progression in clear cell renal cell carcinoma.Cellular and molecular life sciences : CMLS · 2026Article
- TRIM21 suppresses uterine corpus endometrial carcinoma progression by promoting K48 -linked ubiquitination and degradation of SOAT1.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ubiquitination serves as a dynamic post-translational modification that enables rapid and precise regulation of cellular signaling networks. TRIM21, as an important member of the TRIM family, is a protein with E3 ubiquitin ligase activity. By specifically recognizing and ubiquitinating various substrate proteins, it plays a pivotal regulatory role in tumorigenesis and development. Moreover, TRIM21 has been found to play a multi-faceted role in cellular autophagy, metabolic reprogramming, immune escape, tumor proliferation, metastasis and resistance to cell death by regulating the stability and function of key proteins. In this review, we provided an in-depth understanding of the specific mechanism of TRIM21 in different biological processes and tumor types, which contributes to the development of novel targeted therapeutic strategies targeting TRIM21.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.